Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics

[1]  John P. Overington,et al.  PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. , 2020, Cochrane Database of Systematic Reviews.

[2]  R. Langer,et al.  Advances in oligonucleotide drug delivery , 2020, Nature Reviews Drug Discovery.

[3]  Folkert W. Asselbergs,et al.  Genetic drug target validation using Mendelian randomisation , 2020, Nature Communications.

[4]  Chris Wallace,et al.  Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses , 2019, bioRxiv.

[5]  Tom R. Gaunt,et al.  Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes , 2019, Wellcome open research.

[6]  D. Trégouët,et al.  A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process , 2019, Journal of thrombosis and haemostasis : JTH.

[7]  Neil M Davies,et al.  Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes , 2019, Wellcome open research.

[8]  Mark R. Hurle,et al.  Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases , 2019, bioRxiv.

[9]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[10]  David Stacey,et al.  ProGeM: a framework for the prioritization of candidate causal genes at molecular quantitative trait loci , 2018, Nucleic acids research.

[11]  Maria Ryaboshapkina,et al.  Tissue-specific genes as an underutilized resource in drug discovery , 2018, Scientific Reports.

[12]  B. Lamb,et al.  Inflammation as a central mechanism in Alzheimer's disease , 2018, Alzheimer's & dementia.

[13]  Jack Bowden,et al.  Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression , 2018, International journal of epidemiology.

[14]  Mark Davies,et al.  Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005 , 2018, British Medical Journal.

[15]  G. Davey Smith,et al.  Evaluating the potential role of pleiotropy in Mendelian randomization studies , 2018, Human molecular genetics.

[16]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[17]  Pim van der Harst,et al.  Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease , 2017, Circulation research.

[18]  Peter B. Jones,et al.  Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort , 2017, Brain, Behavior, and Immunity.

[19]  D. Gailani,et al.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces , 2017, Seminars in Thrombosis and Hemostasis.

[20]  R. Giugliano,et al.  Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Circulation.

[21]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[22]  Wen Zhang,et al.  A Bayesian Framework for Multiple Trait Colocalization from Summary Association Statistics , 2017, bioRxiv.

[23]  Jessica M B Rees,et al.  Extending the MR‐Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy , 2017, Statistics in medicine.

[24]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[25]  John P. Overington,et al.  PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. , 2017, The Cochrane database of systematic reviews.

[26]  J. Weitz,et al.  Factors XI and XII as Targets for New Anticoagulants , 2017, Front. Med..

[27]  John P. Overington,et al.  The druggable genome and support for target identification and validation in drug development , 2016, Science Translational Medicine.

[28]  Jessica L. Larson,et al.  A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains. , 2017, Journal of Alzheimer's disease : JAD.

[29]  Hashem A. Shihab,et al.  MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations , 2016, bioRxiv.

[30]  S. Humphries,et al.  Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.

[31]  M. Pirinen,et al.  Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA , 2016, Nature Communications.

[32]  Marc Robinson-Rechavi,et al.  A benchmark of gene expression tissue-specificity metrics , 2015, bioRxiv.

[33]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[34]  J. Danesh,et al.  A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease , 2016 .

[35]  D. Rader,et al.  Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial , 2015, The Lancet.

[36]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[37]  Alessandro Vullo,et al.  The Ensembl REST API: Ensembl Data for Any Language , 2014, Bioinform..

[38]  Alex P. Reiner,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[39]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[40]  Donal N. Gorman,et al.  Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions , 2014, PloS one.

[41]  T. Meehan,et al.  An atlas of active enhancers across human cell types and tissues , 2014, Nature.

[42]  C. Wallace,et al.  Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics , 2013, PLoS genetics.

[43]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[44]  Tom R. Gaunt,et al.  Population Genomics of Cardiometabolic Traits: Design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium , 2013, PLoS ONE.

[45]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[46]  F. Dudbridge.  Power and Predictive Accuracy of Polygenic Risk Scores , 2013, PLoS genetics.

[47]  M. Landray,et al.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[48]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[49]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[50]  D. Gaudet,et al.  Gene therapy for lipoprotein lipase deficiency , 2012, Current opinion in lipidology.

[51]  Cholesterol Treatment Trialists' Collaborato.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012 .

[52]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[53]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[54]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[55]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[56]  A. Saiki,et al.  Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. , 2007, Diabetes research and clinical practice.

[57]  G. Gerken,et al.  Lipid metabolism in the liver. , 2007, Zeitschrift fur Gastroenterologie.

[58]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[59]  P. Alderson,et al.  Absence of evidence is not evidence of absence , 2004, BMJ : British Medical Journal.

[60]  K. Tsutsumi,et al.  Lipoprotein lipase activator NO-1886. , 2006, Cardiovascular drug reviews.

[61]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[62]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[63]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[64]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[65]  K. Iwasaki,et al.  The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. , 1993, The Journal of clinical investigation.